(Q34513188)

2 August 2017

5 references

25 April 2019

30 June 2019

19 September 2019

26 October 2020

3 July 2021

Risk evaluation and monitoring in multiple sclerosis therapeutics (English)

1 reference

biomedical investigative technique

2 August 2017

4 references

25 April 2019

30 June 2019

19 September 2019

26 October 2020

1 reference

19 September 2019

immunosuppressive drug

1 reference

26 October 2020

1 reference

3 July 2021

4

Hans-Peter Hartung

1 reference

2 August 2017

Michel C Clanet

1

1 reference

2 August 2017

Jerry S Wolinsky

series ordinal

2

1 reference

2 August 2017

Raymond J Ashton

series ordinal

3

1 reference

2 August 2017

Stephen C Reingold

series ordinal

5

1 reference

2 August 2017

language of work or name

1 reference

30 November 2013

1 reference

Multiple Sclerosis Journal

2 August 2017

1 September 2014

5 references

25 April 2019

30 June 2019

19 September 2019

26 October 2020

3 July 2021

6 references

2 August 2017

25 April 2019

30 June 2019

19 September 2019

26 October 2020

3 July 2021

20

1 reference

2 August 2017

10

1 reference

2 August 2017

1306-1311

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

2 August 2017

5 references

25 April 2019

30 June 2019

19 September 2019

26 October 2020

on focus list of Wikimedia project

3 July 2021

ScienceSource

0 references

cites work

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232326

Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232326

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232326

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232326

Registries, research, and regrets: is the FDA's post-marketing REMS process not adequately protecting patients?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232326

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232326

Managing the risks of immunosuppression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232326

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232326

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232326

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232326

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232326

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232326

Prospect theory on the brain? Toward a cognitive neuroscience of decision under risk

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232326

The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232326

Interferon in relapsing-remitting multiple sclerosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232326

Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232326

A Tutorial Introduction to Decision Theory

7 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513207

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513207

Shared decision making to improve care and reduce costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513207

Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513207

What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513513207

Risks and benefits of multiple sclerosis therapies: need for continual assessment?

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/24293456

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists

1 reference

https://pubmed.ncbi.nlm.nih.gov/24293456

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report

1 reference

https://pubmed.ncbi.nlm.nih.gov/24293456

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1177/1352458513513207

1 reference

2 August 2017

1 reference

2 August 2017

1 reference